Please ensure Javascript is enabled for purposes of website accessibility
Sackler-Owned Opioid Maker Pushes Overdose Treatment Abroad
gvw_ap_news
By Associated Press
Published 5 years ago on
December 16, 2019

Share

The gleaming white booth towered over the medical conference in Italy in October, advertising a new brand of antidote for opioid overdoses. “Be prepared. Get naloxone. Save a life,” the slogan on its walls said.

“You’re in the business of selling medicine that causes addiction and overdoses, and now you’re in the business of selling medicine that treats addiction and overdoses? That’s pretty clever, isn’t it?” — Dr. Andrew Kolodny, an outspoken critic of Purdue
Some conference attendees were stunned when they saw the company logo: Mundipharma, the international affiliate of Purdue Pharma — the maker of the blockbuster opioid, OxyContin, widely blamed for unleashing the American overdose epidemic.
Here they were cashing in on a cure.
“You’re in the business of selling medicine that causes addiction and overdoses, and now you’re in the business of selling medicine that treats addiction and overdoses?” asked Dr. Andrew Kolodny, an outspoken critic of Purdue who has testified against the company in court. “That’s pretty clever, isn’t it?”
As Purdue Pharma buckles under a mountain of litigation and public protest in the United States, its foreign affiliate, Mundipharma, has expanded abroad, using some of the same tactics to sell the addictive opioids that made its owners, the Sackler family, among the richest in the world. Mundipharma is also pushing another strategy globally: From Europe to Australia, it is working to dominate the market for opioid overdose treatment.
“The way that they’ve pushed their opioids initially and now coming up with the expensive kind of antidote — it’s something that just strikes me as deeply, deeply cynical,” said Ross Bell, executive director of the New Zealand Drug Foundation and a longtime advocate of greater naloxone availability. “You’ve got families devastated by this, and a company who sees dollar signs flashing.”
This story was produced with support from the Pulitzer Center on Crisis Reporting.
___
Photo of OxyContin pills
FILE – This Feb. 19, 2013, file photo shows OxyContin pills arranged for a photo at a pharmacy, in Montpelier, Vt. Five state attorneys general announced lawsuits Thursday, May 16, 2019, seeking to hold the drug industry responsible for an opioid addiction crisis that has become the biggest cause of accidental deaths across the country and in many states. The new filings in Iowa, Kansas, Maryland, West Virginia and Wisconsin mean 45 states have now taken legal action in recent years against Purdue Pharma, the maker of OxyContin. Some of the states are also suing Richard Sackler, a former president and member of the family that owns the Connecticut-based firm. (AP Photo/Toby Talbot, File)
Mundipharma’s antidote, a naloxone nasal spray called Nyxoid, was recently approved in New Zealand, Europe and Australia. Mundipharma defended it as a tool to help those whose lives are at risk, and even experts who criticize the company say that antidotes to opioid overdoses are badly needed. Patrice Grand, a spokesman for Mundipharma Europe, said in a statement that heroin is the leading cause of overdose death in European countries and nasal naloxone is an important treatment option.
Injectable naloxone has long been available; it is generic and cheap. But Mundipharma’s Nyxoid is the first in many countries that comes pre-packaged as a nasal spray — an easier, less threatening way for those who witness an overdose to intervene. Nyxoid, which isn’t sold in the U.S., is more expensive than injectable naloxone, running more than $50 a dose in some European countries. A similar product manufactured by another pharmaceutical company has been available for years in the U.S. under the brand name Narcan.
Critics say Nyxoid’s price is excessive, particularly when inexpensive naloxone products already exist. Grand declined to say how much Nyxoid costs Mundipharma to manufacture or how profitable it has been.
The Sackler family’s pharmaceutical empire has long considered whether it might make money treating addiction, according to lawsuits filed against Purdue and the family. In the U.S., Purdue Pharma called its secret proposal Project Tango, the attorneys general of Massachusetts and New York have alleged, and discussed it in a September 2014 conference call that included family member Kathe Sackler.
In internal documents, the lawsuits allege, Purdue illustrated the connection they had publicly denied between opioids and addiction with a graphic of a blue funnel. The top end was labeled “Pain treatment.” The bottom: “opioid addiction treatment.” The slideshow said they had an opportunity to become an “end-to-end provider” — opioids on the front end, and addiction treatment on the back end.
“It is an attractive market,” the staff wrote, according to the Massachusetts complaint. “Large unmet need for vulnerable, underserved and stigmatized patient population suffering from substance abuse, dependence and addiction.”

Project Tango Fizzled in the U.S.

In its response to the court, the family’s lawyers wrote that the plan was put forward by a third-party private equity fund as a potential joint venture and “at the very most, Project Tango was mentioned in passing on a few occasions and the proposal was subsequently abandoned.” A press release issued by the Sacklers said no member of the family or board had an active role in the presentations or supported the proposal, and called the lawsuits “sensationalized” and “misleading.” Purdue declined to comment.

The lawsuit alleges that Purdue identified its own painkiller patients as a target market for naloxone — and that it could use its sales force already visiting doctors to promote opioids to also promote overdose reversal medication.
New York’s lawsuit alleges that in 2015, Project Tango was presented to Purdue’s board as a joint venture to sell the addiction medication suboxone that could become the “market lead in the addiction medicine space.” The presentation highlighted the sales opportunity in opioid addiction: 40 to 60 percent who went through treatment would relapse and need it again.
Project Tango stalled. It was revised the next year with a new plan to sell naloxone, the lawsuits allege.
Publicly, Purdue was denying that its painkillers caused the addiction epidemic. But in internal communications, the company described naloxone as a “strategic fit” and a “complementary” product to the prescription opioids they were already selling, the Massachusetts attorney general said. Purdue calculated that the need for overdose reversal medication was increasing so rapidly, potential revenue could triple from 2016 to 2018.
The lawsuit alleges that Purdue identified its own painkiller patients as a target market for naloxone — and that it could use its sales force already visiting doctors to promote opioids to also promote overdose reversal medication. They saw potential profits in government efforts to expand access to naloxone to stem the tide of overdose deaths, a toll that has soared to 400,000 since the American epidemic began.
Project Tango fizzled in the U.S.; the family’s press release said Purdue’s board rejected it.

Health and Addiction Experts Also Praised the Drug’s Life-Saving Potential

But half a world away, in Australia, Mundipharma embarked on an effort to promote naloxone that was sweeping and effective.
As part of an Australian coroner’s investigation last year into six fatal opioid overdoses in New South Wales state, Mundipharma submitted a 15-page document touting the benefits of naloxone. If people around the overdose victims had had access to naloxone, the company wrote, many of those deaths may have been avoided. At the same time, Mundipharma was registering Nyxoid in Australia, a fact it acknowledged within its submission.
In the document, the company suggested that officials change the country’s laws to allow for easier access to naloxone, get naloxone into needle exchange programs, detox centers and supervised injecting clinics, and establish a national, free take-home naloxone program.
“The Coroner should consider what is needed to realise the full public health benefits of this essential medicine,” Mundipharma wrote.
During the coroner’s inquest, Mundipharma sent a staffer to court to testify about the benefits of naloxone nasal spray. According to a transcript, Mundipharma’s Medical Affairs Director, Brian Muller, came to court with samples of naloxone products, including Nyxoid.
Health and addiction experts also praised the drug’s life-saving potential. In her written findings delivered in March, Coroner Harriet Grahame agreed that naloxone should be more widely distributed and Nyxoid given to the state’s paramedics, police agencies, doctors and hospital emergency departments.
Mundipharma also paid for a drug policy institute’s study on naloxone that the federal government ultimately used as a blueprint for a 10 million Australian dollar ($6.8 million) pilot program to distribute naloxone, including Nyxoid. And in October, Australian Health Minister Greg Hunt announced that Australia’s government would subsidize Nyxoid prescriptions, meaning it costs Australians as little as AU$6.50 ($4.50) per pack, versus around AU$50 without the subsidy.

Photo of a sign at the Mundipharma International headquarters at Cambridge Science Park in England
This Dec. 12, 2019, photo shows the Mundipharma International headquarters at Cambridge Science Park in England. Mundipharma is the international affiliate of Purdue Pharma, the maker of the blockbuster painkiller OxyContin. Mundipharma is now marketing Nyxoid, a new brand of naloxone, an opioid overdose reversal medication. (AP Photo/Leila Coker)

In Some Countries, Nyxoid Is the Only Nasal Naloxone Product Approved

Asked in an interview whether the government had any concerns about following the recommendations of a Mundipharma-funded report that stood to benefit the company financially, Hunt replied: “All of the advice is that this is a product that will save lives and protect lives and our approach is to be fearless of the source of the product.”
In a statement, Mundipharma Australia denied its Nyxoid push in the country had any connection to, or was influenced in any way, by Purdue’s Project Tango.
“Mundipharma Australia and Purdue Pharma are independent companies,” the Australian company wrote. “Mundipharma Australia introduced Nyxoid to help meet a clear clinical need.”
Grand, the spokesman for Mundipharma Europe, also rejected any link between the company’s Nyxoid strategy and Project Tango, saying that the European company and Purdue have separate managements, boards and strategies.
In some countries, including Norway, Nyxoid is the only nasal naloxone product approved, said Thomas Clausen, a professor at the University of Oslo in Norway who runs the nation’s naloxone program. Clausen is happy that Nyxoid is available, but not that a company profiting from mass marketing opioids is now trying to profit again off opioid addiction.
“It’s kind of a paradox,” he said.
Clausen said he hopes other companies will enter the market, and that competition will drive down cost. In its basic, generic form, Clausen said, naloxone is so cheap that the United Nations launched a pilot program in central Asian countries providing injectable naloxone at a cost of around $1 per kit.
Some critics argue that Mundipharma should be providing a cheaper — or even free — naloxone product, although Nyxoid’s cost is not remarkable when compared to the exorbitant price of many prescription drugs in the U.S. The most common nasal antidote in the U.S. retails for more than $100, double what most Europeans pay for Nyxoid.

In the United Kingdom, Nyxoid Is Being Distributed by a Handful of Charities

Still, in some countries, Nyxoid’s price could prove problematic.
Pernilla Isendahl runs a naloxone distribution program in a county in south Sweden that began in June 2018, when Nyxoid came onto the market. Each kit costs the government 450 Swedish Krona ($47.)

“If they were trying to find a solution, they would just distribute naloxone for free. They could use all that money they made off opioids to help support a program where they are giving away this life-saving medication.” Stephen Wood, a fellow at the Harvard Medical School Center for Bioethics
The project is expected to run for at least three years, and she hopes after that the county will continue to pay for the medication, despite budget constraints.
“I can’t really see how it would be financed by the people themselves, at the price it is now,” she said.
In the United Kingdom, Nyxoid is being distributed by a handful of charities, said Peter Furlong, coordinator of British charity Change Grow Live’s Nyxoid distribution pilot program in Manchester. Furlong is pleased more people now have access to the medicine, but it still costs more than injectable naloxone. Furlong said he asked Mundipharma if they could reduce the drug’s price for the charity’s pilot, which began in August, but Mundipharma told him it was too early to talk discounts.
Grand, the spokesman for Mundipharma Europe, said the company was working closely with charities and addiction organizations to identify the best ways to make the drug available to those who may benefit from it. Nyxoid’s price reflects the company’s investment, manufacturing cost and the value of the technology, while recognizing the “prevailing financial pressures that exist within care sectors,” he said.
Stephen Wood, a fellow at the Harvard Medical School Center for Bioethics who studied how pharmaceutical companies in the U.S. raised prices on naloxone products as the addiction epidemic intensified, says that Sackler-owned companies manufacturing naloxone have an ethical duty to make it widely available.
“If they were trying to find a solution, they would just distribute naloxone for free,” he said. “They could use all that money they made off opioids to help support a program where they are giving away this life-saving medication.”

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Misty Her: Push for Fresno Unified Turnaround Starts Now With ‘Boots on the Ground’

DON'T MISS

Fresno Police Arrest 17 in Domestic Violence Crackdown

DON'T MISS

What’s Next for Fresno Smoke Shop Ordinance: Lawsuit, Veto, Override?

DON'T MISS

Visalia Man Sentenced to Life in Prison for 2019 Fatal Stabbing

DON'T MISS

Fresno Man Arrested in 2004 Cold Case Rape and Murder

DON'T MISS

Valley Crime Stoppers’ Most Wanted Person of the Day: Willie Ray Butler

DON'T MISS

California’s Economy Ranks Fourth Worldwide, Surpasses Japan

DON'T MISS

Fresno County Traffic Stop Leads to $600K Cocaine Bust

DON'T MISS

Fresno Ranks Fourth in US for an Affordable Night Out

DON'T MISS

New US SEC Chair Says Crypto Sector Deserves Clear Regulations

UP NEXT

China Exempts Some Goods From US Tariffs

UP NEXT

Trump Poised to Offer Saudi Arabia Over $100 Billion Arms Package, Sources Say

UP NEXT

On Major Economic Decisions, Trump Blinks, and Then Blinks Again

UP NEXT

Two From Search Group That Uncovered Mexico’s ‘Ranch of Horror’ Killed

UP NEXT

Chicago Bears Great Steve McMichael Dies at 67 After Battle With ALS

UP NEXT

Long Wait Is Over for Cam Ward, Travis Hunter and Other Draft Prospects Joining the NFL

UP NEXT

Golden State’s Jimmy Butler Injured in Game 2 Loss, His Status for Game 3 Unknown

UP NEXT

Jalen Green Makes Eight 3s to Help Rockets Even Series With Warriors

UP NEXT

Israeli Fire Kills at Least 44 People in Gaza, Hits a Police Station

UP NEXT

Trump Tells Putin to ‘STOP’ After Russian Attacks Kills 10 in Kyiv

Visalia Man Sentenced to Life in Prison for 2019 Fatal Stabbing

2 hours ago

Fresno Man Arrested in 2004 Cold Case Rape and Murder

3 hours ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Willie Ray Butler

3 hours ago

California’s Economy Ranks Fourth Worldwide, Surpasses Japan

3 hours ago

Fresno County Traffic Stop Leads to $600K Cocaine Bust

3 hours ago

Fresno Ranks Fourth in US for an Affordable Night Out

3 hours ago

New US SEC Chair Says Crypto Sector Deserves Clear Regulations

4 hours ago

US Officials Arrest Milwaukee Judge for Obstructing Immigration Operation

4 hours ago

Exclusive: US Congress Republicans Seek $27 Billion for Golden Dome in Trump Tax Bill

5 hours ago

China Exempts Some Goods From US Tariffs

5 hours ago

Misty Her: Push for Fresno Unified Turnaround Starts Now With ‘Boots on the Ground’

After becoming the first female superintendent for Fresno Unified and the first Hmong superintendent in the nation, Misty Her has been takin...

9 minutes ago

9 minutes ago

Misty Her: Push for Fresno Unified Turnaround Starts Now With ‘Boots on the Ground’

Fresno police are seeking two suspects who stole several boxes of shoes from the WSS store on East Cesar Chavez Boulevard on February 20, 2025.
16 minutes ago

Fresno Police Arrest 17 in Domestic Violence Crackdown

1 hour ago

What’s Next for Fresno Smoke Shop Ordinance: Lawsuit, Veto, Override?

A Tulare County jury convicted Isaiah Elias Garcia, 25, on Friday, March 28, 2025, of second-degree murder for fatally stabbing a man during a 2019 fight in Visalia. (Tulare County DA)
2 hours ago

Visalia Man Sentenced to Life in Prison for 2019 Fatal Stabbing

Robert Castillo (left), 61, of Fresno, has been arrested in the 2004 murder and sexual assault of Barbara Lee after DNA evidence linked him to the cold case and two additional rape investigations. (Fresno County SO)
3 hours ago

Fresno Man Arrested in 2004 Cold Case Rape and Murder

Willie Ray Butler is Valley Crime Stoppers' Most Wanted Person of the Day for April 25, 2025. (Valley Crimes Stoppers)
3 hours ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Willie Ray Butler

3 hours ago

California’s Economy Ranks Fourth Worldwide, Surpasses Japan

A CHP K-9 unit discovered 13 pounds of cocaine worth over $600,000 hidden in a vehicle's exhaust tunnel during a traffic stop on I-5 in Fresno County on Thursday, April 24, 2025. (CHP)
3 hours ago

Fresno County Traffic Stop Leads to $600K Cocaine Bust

Help continue the work that gets you the news that matters most.

Search

Send this to a friend